This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.
Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention
by Zacks Equity Research
FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
by Zacks Equity Research
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More
by Zacks Equity Research
Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.
The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.
Gilead Sciences (GILD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 15.30% and 6.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Halloween Nightmare Market Close: Q3 Reports for PINS, ETSY, GILD & F
by Mark Vickery
The Nasdaq led the way down, -3.7% or 426 points; the S&P 500 dropped 3.5% or 120 points; and the Dow, just off session lows at the end of the normal trading day, fell 3.4% or 943 points.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.
Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.
Should You Buy Gilead (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
Will Covid-Led Higher Demand Aid Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
A surge in demand for virtual health care services is likely to have contributed to Teladoc's (TDOC) earnings in Q3
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Werner, Carlisle, Gilead, Intel and Mattel as Zacks Bull and Bear of the Day
by Zacks Equity Research
Werner, Carlisle, Gilead, Intel and Mattel as Zacks Bull and Bear of the Day
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.